preloader
Edit Content

About Us

BioSen Pharma was founded to address the growing need for specialized expertise in clinical research and health innovations across Africa and other emerging regions. We bring together international experience and regional understanding to make health innovations accessible where it is needed most.

Contact Info

Biosimilars Beyond Borders: Lessons from Europe — What Africa Can Learn

Two Continents, One Goal: Affordable Biologics for All

Europe’s leadership in biosimilars has reshaped how the world thinks about access to biologic medicines. When the European Medicines Agency (EMA) approved Omnitrope (somatropin) in 2006, it marked the beginning of a new era: one where affordability, safety, and innovation could coexist.

A biosimilar is defined by the EMA as a biological medicine that is highly similar to another already approved biological medicine: the “reference medicine” or “reference medicinal product”. Like all biologics, these medicines are produced from living systems such as human, animal, or microbial cells. Because of their biological origin and molecular complexity, small natural variations exist between manufacturing batches, making production of exact copies impossible. What defines a biosimilar, however, is not identicality but equivalence in safety, quality, and efficacy.

To read more download the document